USPTO serial 77307521
Serial No. 77307521
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BENMAMAN, ALICE
- Law office
- DIVISIONAL UNIT
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 77307521?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Lee Taylor
Jennifer Lee Taylor MORRISON & FOERSTER LLP425 MARKET STREETSAN FRANCISCO, CA 94105-2482UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for use in the treatment of cardiovascular diseases and disorders, urological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, hypertension, inflammation and inflammatory diseases and disorders, metabolic diseases and disorders, infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, psychiatric diseases and disorders, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, and hemolytic diseases and disorders; pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, ophthalmologic preparations, smoking cessation preparations, tissue and skin repair preparations and gynecological preparations; drug delivery devices, namely, inhalers containing pre-filled drug cartridges which deliver medication in liquid form via the pulmonary route, either directly to the lungs or for absorption and delivery in systemic circulation for use in the treatment of cardiovascular diseases and disorders, urological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, hypertension, inflammation and inflammatory diseases and disorders, metabolic diseases and disorders, infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, psychiatric diseases and disorders, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, and hemolytic diseases and disorders; drug delivery devices, namely, inhalers containing pre-filled drug cartridges which deliver medication in liquid form via the pulmonary route, either directly to the lungs or for absorption and delivery in systemic circulation for use in the delivery of cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, ophthalmologic preparations, smoking cessation preparations, tissue and skin repair preparations and gynecological preparations | ACTIVE | — |
| 042 | Pharmaceutical research and development; research and development of pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, urological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, inflammation and inflammatory diseases and disorders, metabolic diseases and disorders, respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, and hemolytic diseases and disorders; research and development of pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, ophthalmologic preparations, smoking cessation preparations, tissue and skin repair preparations and gynecological preparations; research and development of drug delivery devices, both with and without pre-filled drug cartridges, for delivery of medication via the pulmonary route; medical and scientific research, namely, conducting clinical trials | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 5, 2011 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 5, 2011 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 4, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Sep 3, 2010 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 1, 2010 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 1, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 27, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Apr 26, 2010 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 23, 2010 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 23, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 9, 2009 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 6, 2009 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 6, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 20, 2009 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 19, 2009 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 19, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 18, 2008 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Nov 18, 2008 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 17, 2008 | PAPER RECEIVED | — | |
| Nov 17, 2008 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 13, 2008 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Nov 13, 2008 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 13, 2008 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 3, 2008 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 11, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 20, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 1, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 31, 2008 | CNEA | EXAMINER'S AMENDMENT MAILED | — |
| Jan 30, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 30, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 30, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 29, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 26, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 26, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 26, 2007 | ALIE | ASSIGNED TO LIE | — |
| Nov 15, 2007 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Oct 24, 2007 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Oct 23, 2007 | NWAP | NEW APPLICATION ENTERED | — |